Hangzhou Tigermed Consulting300347.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Hangzhou Tigermed Consulting (300347.SZ) trades at a P/E of 472.00x, P/B of 2.22x, P/S of 5.81x, and a dividend yield of 0.26%.
Longitudinal percentile comparison: P/E sits at the 98th percentile over the trailing 10Y window (vs. 94th percentile over 3Y); P/B sits at the 14th percentile over the trailing 10Y window (vs. 45th percentile over 3Y); P/S sits at the 5th percentile over the trailing 10Y window (vs. 16th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 96th percentile within its industry and the 97th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.01%, ranking at the 80th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 83.8 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 0.26% comes from cash dividends, with an implied ~0.75% from buybacks — a fairly balanced mix of both channels. Hangzhou Tigermed Consulting operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300347 · SZSE: 300347 · 300347
Want the full picture on whether Hangzhou Tigermed Consulting (300347.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 472.00 | ||||||
| P/B (MRQ) | 2.22 | ||||||
| P/S (TTM) | 5.81 | ||||||
| Dividend Yield | 0.26% | ||||||
| Buyback + Div Yield | 1.01% |